LAKEWOOD, NJ, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: RELI) (“Reliance”, “we” or the “Company”) today announced that it has deployed additional cash to increase its Zcash (ZEC) position. This additional allocation to the Company’s Digital Asset Treasury (“DAT”) reflects the Company’s internal view that ZEC may be an institutionally adaptable and technologically resilient privacy-enabled digital asset and may play a meaningful role in its long-term treasury strategy. Zcash’s du ...

Core Insights - CaliberCos Inc. has selected Coinbase Global Inc. to provide institutional trading and custody for its Digital Asset Treasury strategy focused on Chainlink's LINK token [1] - CaliberCos claims to be the first Nasdaq-listed company to adopt a treasury reserve policy centered on LINK [2] - The company's stock has experienced a significant decline of over 53% in the past year [2] Company Strategy - Caliber intends to accumulate LINK over time, hold it long-term, and seek yield opportunities, viewing this strategy as complementary to its real estate investments [3] - The Digital Asset Treasury plan aims to provide shareholders with mark-to-market exposure to a blockchain infrastructure asset [2][3] Market Performance - Following the announcement, Caliber's stock initially rose but later fell approximately 4%, trading around $5.94 [1][4] - Coinbase's stock has seen a substantial increase of over 95% in the past year, indicating strong market performance [4]

Core Insights - Artelo Biosciences, Inc. is advancing its clinical pipeline with multiple announcements of clinical data results anticipated in Q3 2025, focusing on treatments for cancer, pain, and neurological conditions [1] Business Highlights - ART26.12 is progressing towards a multi-dose Phase 1 safety study, with positive safety and pharmacokinetics demonstrated in a completed Phase 1 Single Ascending Dose (SAD) study [2][7] - ART27.13 is on track for a Phase 2 readout in Q3 2025, targeting cancer anorexia-cachexia syndrome, a condition with no FDA-approved therapies [3][11] - ART12.11 is showing promise in treating depression and cognitive decline, with plans to initiate human trials in early 2026 [4][8] Financial Results - For Q2 2025, the company reported a net loss of $3.2 million, or $5.61 per share, compared to a net loss of $2.4 million, or $4.52 per share in Q2 2024 [14] - Research and development expenses were $1.9 million for the quarter, up from $1.7 million in the same period in 2024, while general and administrative expenses increased to $1.3 million from $0.8 million [9] Cash and Investments - As of June 30, 2025, cash and investments totaled $2.1 million, with recent funding activities including $0.9 million in convertible notes and a private placement yielding $1.425 million [14] - Subsequent to June 30, 2025, the company completed a PIPE transaction for gross proceeds of $9.475 million, alongside a strategy to invest in the digital currency Solana [14][15]